Results 91 to 100 of about 5,114,489 (264)
PLoS ONE, 2015 Zoledronic acid, a highly potent nitrogen-containing bisphosphonate used for the treatment of pathological bone loss, is excreted unmetabolized via the kidney if not bound to the bone.
Anja Verhulst +3 more
doaj +1 more source
MedComm, Volume 6, Issue 12, December 2025.Lung cancer represents a significant global health threat. Despite progress in treatment, metastasis continues to present a major clinical challenge. This article reviews the metastases of lung cancer to the liver, bone, and brain, focusing on clinical symptoms, molecular mechanisms, and treatment strategies.
Yunkui Zhang +4 more
wiley +1 more source
Pediatric Blood &Cancer, Volume 72, Issue 12, December 2025.ABSTRACT Background Hypercalcemia is rarely observed in pediatric patients with cancer. However, rare cases of renal insufficiency and osteoporosis have been reported as severe consequences. Published literature focuses predominantly on hypercalcemia in pediatric hematologic malignancies, precluding causative associations with solid tumor disease ...
Felicia Y. Ho +5 more
wiley +1 more source
Short-term effect of zoledronic acid upon fracture resistance of the mandibular condyle and femoral head in an animal model [PDF]
, 2013 Objective: The aim of this study was to compare the effects in terms of resistance to fracture of the mandibular condyle and femoral head following different doses of zoledronic acid in an animal model.
Camacho Alonso, Fabio +2 more
core +1 more source
The contemporary management of prostate cancer
CA: A Cancer Journal for Clinicians, Volume 75, Issue 6, Page 552-586, November/December 2025.Abstract Prostate cancer is the most common cancer in two thirds of the world, with an expected doubling in both incidence and mortality in the next two decades. No strong environmental associations exist for the development of prostate cancer; therefore, lifestyle measures are unlikely to mitigate this increasing burden.
Deep Chakrabarti +11 more
wiley +1 more source
The Effect of Zoledronic Acid on BSP Expression and Methylation during Osteoblastic Differentiation of Mesenchymal Stem Cells [PDF]
پیاورد سلامت, 2011 Background and Aim: Bone sialoprotein (BSP) is a specific marker of osteoblastic differentiation. In this research, the effect of Zoledronic Acid on BSP expression and methylation status during osteoblastic differentiation of mesenchymal stem cells (MSCs)
M Mahmodi Niya Meymand +5 more
doaj +2 more sources
Codelivery of zoledronic acid and double-stranded RNA from core-shell nanoparticles
International Journal of Nanomedicine, 2013 Li Chen,1 Yunfei Ding,2 Yongzhong Wang,3 Xingrong Liu,2 RJ Babu,1 WR Ravis,1 Weili Yan21Department of Pharmaceutical Sciences, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA; 2Department of Pharmaceutical Sciences, College of Life ...
Yan W +6 more
doaj
OUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH NON- SMALL CELL LUNG CANCER AND BONE METASTASES [PDF]
Journal of IMAB, 2013 Objective: Bone metastases occur in 30- 40% of patients with lung cancer. The aim of this study was to assess the efficacy and safety of Zoledronic acid, a third generation biphosphonates, in patients with non- small cell lung cancer and bone metastases.
Deyan N. Davidov
doaj +1 more source
The FASEB Journal, 2019 Bisphosphonate‐related osteonecrosis of the jaw (BRONJ) is a detrimental side effect of the long‐term administration of bisphosphonates. Although macrophages were reported to be an important mediator of BRONJ, the detailed potential mechanism of BRONJ ...
Weiwen Zhu +7 more
semanticscholar +1 more source
Molecular Oncology, Volume 19, Issue 11, Page 3387-3408, November 2025.Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source